Le Nouvel Hôpital civil de Strasbourg est constitué de deux bâtiments et occupe une surface totale de 90 000 m². Il est situé sur le site de l'Hôpital civil. Il a ouvert le 31 mars 2008.

During the past decade, Nouvel Hôpital Civil conducted 147 clinical trials. In the 10-year time frame, 147 clinical trials started and 58 clinical trials were completed, i.e. on average, 39.5% percent of trials that started reached the finish line to date. In the past 5 years, 63 clinical trials started and 42 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Nouvel Hôpital Civil" #1 sponsor was "Intergroupe Francophone de Cancerologie Thoracique" with 19 trials, followed by "Hoffmann-La Roche" with 8 trials sponsored, "Celgene" with 7 trials sponsored, "Pfizer" with 6 trials sponsored and "University Hospital, Strasbourg, France" with 6 trials sponsored. Other sponsors include 190 different institutions and companies that sponsored additional 127 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Nouvel Hôpital Civil" #1 collaborator was "Ministry of Health, France" with 9 trials as a collaborator, "Intergroupe Francophone de Cancerologie Thoracique" with 4 trials as a collaborator, "Merck Sharp & Dohme LLC" with 4 trials as a collaborator, "Roche Pharma AG" with 4 trials as a collaborator and "University Hospital, Tours" with 4 trials as a collaborator. Other collaborators include 106 different institutions and companies that were collaborators in the rest 103 trials.

According to Clinical.Site data, the most researched conditions in "Nouvel Hôpital Civil" are "Carcinoma, Non-Small-Cell Lung" (9 trials), "Non Small Cell Lung Cancer Metastatic" (4 trials), "Pulmonary Arterial Hypertension" (4 trials), "Breast Neoplasms" (3 trials) and "Coronary Artery Disease" (3 trials). Many other conditions were trialed in "Nouvel Hôpital Civil" in a lesser frequency.

Most popular intervention types in "Nouvel Hôpital Civil" are "Drug" (142 trials), "Device" (41 trials), "Other" (28 trials), "Biological" (23 trials) and "Procedure" (14 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (42 trials), "Pemetrexed" (12 trials), "Carboplatin" (8 trials), "Cisplatin" (7 trials) and "Pembrolizumab" (6 trials). Other intervention names were less common.

The vast majority of trials in "Nouvel Hôpital Civil" are 228 trials for "All" genders, 8 trials for "Female" genders and 5 trials for "Male" genders.

Currently, there are 75 active trials in "Nouvel Hôpital Civil". 2 are not yet recruiting, 37 are recruiting, 34 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 120 completed trials in Nouvel Hôpital Civil, undefined suspended trials, and 29 terminated clinical trials to date.

Out of the total trials that were conducted in Nouvel Hôpital Civil, 9 "Phase 1" clinical trials were conducted, 64 "Phase 2" clinical trials and 94 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 11 trials, and there were also 35 trials that are defined as “Not Applicable".